Israeli start-up Vectorius has developed a tiny pressure sensor, just 3 mm in size and without a battery, that is implanted in the heart to help heart failure patients manage their condition. The sensor transmits data through a dedicated application, allowing patients to adjust their medication dosage and improve their quality of life.
A recent pilot study examined the safety, usability, and performance of the system and therapeutic paradigm developed by Vectorius. The results showed that self-management based on left atrium pressure is safe and effective, with no complications or side effects after 12 months of follow-up. The sensor’s stability and accuracy remained consistent throughout, with patients showing high cooperation for treatment leading to significant improvements in quality of life indicators and reduced hospitalizations due to heart failure.
The observed clinical effect is attributed to patients avoiding very high left ventricle pressures, which can lead to issues like pulmonary congestion and edema requiring hospitalization. Additionally, transferring control to the patient has a positive behavioral component in enhancing treatment effects. Patients receiving immediate feedback were able to balance their medication and lifestyle effectively.
Vectorius already has 55 transplant recipients in Israel and Europe with over 40,000 cumulative follow-up days. This summer, transplants are planned at top heart centers in the US as part of the ongoing expansion of the clinical trial. Eyal Orion, co-founder and CEO of Vectorius, sees the publication of the research as a historic milestone for the company, which has been developing advanced technology and a new therapeutic method for over a decade. The company aims to fundamentally change the understanding and treatment of heart diseases, positioning Israel as a pioneer in the field with a significant impact on millions of patients worldwide.
Established in 2011 by Dr. Eyal Orion and Oren Goldstein, Vectorius has 100 employees in Israel and has received funding from various investors including the Zisapel family, Zohar Gilon
